Back to the Library
Jenner & Block Partner Martin C. Glass led a firm team in representing Clementia Pharmaceuticals Inc., a Montreal, Canada-based clinical stage biopharmaceutical company, in its public offering of common shares and Nasdaq listing. The total offering size was 5,300,000 common shares for gross proceeds of approximately $70.2 million. The offering was expected to close on November 1, 2018, subject to customary closing conditions. In addition, Clementia has granted the underwriters a 30-day option to purchase up to an additional 795,000 common shares from it at the public offering price, less underwriting discounts and commissions.
Morgan Stanley and Leerink Partners are acting as book-running managers for the offering. Wedbush PacGrow is acting as the co-manager for the offering.